McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

McKesson Earnings Call Highlights Growth, Cash Power

AI-generated analysis

πŸ“ˆ McKesson reported fiscal 2026 revenue growth of 12% to reach $403.0 billion with adjusted operating profit increasing 15% to $6.5 billion.

πŸ’° Adjusted earnings per share rose 18% year-over-year to $39.11, driven by strong core operations and excluding prior-year McKesson Ventures gains.

πŸ“Š The fourth quarter revenue increased 6% to $96.3 billion while adjusted EPS advanced 16% to $11.69 due to effective cost management.

πŸ’΅ Cash generation remained robust with fiscal 2026 operating cash flow of $6.2 billion and free cash flow of $5.4 billion.

πŸ”„ The company returned $5.1 billion to shareholders through buybacks and dividends, including a $2.25 billion accelerated repurchase in Q4.

⚑ Oncology revenue surged 35% in Q4 to $12.7 billion as the segment added over 570 providers, marking its largest net increase since 2010.

πŸ₯ Biopharma services supported a record 3.4 million patients with productivity gains, enabling each employee to care for approximately 120 more patients than last year.

πŸ’Š GLP-1 distribution revenue jumped 22% in Q4 to $14 billion as the category continues to serve as a major growth driver.

πŸ€– Investments in automation and AI at new locations like the Montreal distribution center are driving working capital savings and supply chain resilience.

πŸ› The Medical-Surgical separation advanced with financing steps completed, including a $1.0 billion term loan and Apollo's $1.25 billion minority investment.

⚠️ Branded pharmaceutical price declines negatively impacted reported revenue by cutting year-over-year growth by approximately 3% in the quarter.

πŸ“‰ GLP-1 volumes showed quarterly volatility with a 4% sequential decline in Q4, which management attributed to inventory adjustments and supply patterns.

🩹 The Medical-Surgical Solutions segment posted modest Q4 revenue growth of 1% while operating profit decreased 5% to $271 million.

βš–οΈ Management cautioned investors to exclude GAAP-only items like a $480 million gain on the Norway divestiture when analyzing underlying trends.

πŸ“‰ Operating expenses increased 14% in Q4 to $2.1 billion reflecting continued investments in strategic growth initiatives.

Bullish Signals
  • McKesson delivered another year of double-digit growth with fiscal 2026 revenue climbing 12% to $403.0 billion and adjusted operating profit rising 15% to $6.5 billion.
  • Adjusted EPS increased 18% to $39.11, and management emphasized that underlying EPS growth was closer to 20%, underscoring the strength of core operations excluding one-time McKesson Ventures gains.
  • The fourth quarter capped the year on a solid note with revenue rising 6% to $96.3 billion and adjusted EPS advancing 16% to $11.69.
  • McKesson generated robust cash flow with fiscal 2026 operating cash flow of $6.2 billion and free cash flow of $5.4 billion, returning $5.1 billion to shareholders via buybacks and dividends.
  • Management secured Board approval for an additional $5.0 billion in share repurchases, bringing total repurchase capacity to roughly $7.7 billion.
  • Oncology and multispecialty operations were standout performers with Q4 revenue up 35% to $12.7 billion and operating profit surging 53% to $385 million.
  • The oncology segment added more than 570 providers in the quarter, its largest net increase since 2010, supported by strategic acquisitions like PRISM and Core Ventures.
  • GLP-1 revenues surged year over year with Q4 distribution revenue jumping 22% to $14 billion and full-year revenue increasing 27% to $53 billion.
  • Biopharma services delivered record annual verifications supporting a record 3.4 million patients, while productivity gains allowed each employee to support about 120 more patients than last year.
  • A new Montreal distribution center with advanced automation and AI-driven storage is already driving working capital savings and helping navigate disruptions like winter storms with minimal customer impact.
  • McKesson completed key financing steps for the Medical-Surgical separation, including a $1.0 billion term loan and $1.0 billion revolver, alongside a $1.25 billion minority investment from Apollo.
Risk Factors
  • Branded pharmaceutical price declines reduced reported revenue growth by approximately 3% in the quarter, weighing on overall top-line performance.
  • GLP-1 category revenue experienced a 4% sequential decline in Q4 due to supply patterns and inventory adjustments, introducing forecasting noise for investors.
  • The Medical-Surgical Solutions segment showed weak performance with Q4 operating profit down 5% to $271 million despite modest top-line growth of just 1%.
  • Fiscal 2027 guidance for the Medical-Surgical unit points to only low single-digit revenue growth and flat-to-modest profit gains, indicating limited upside potential.
  • The separation of the Medical-Surgical business depends on pending financing and regulatory approvals, adding significant execution risk to the strategic transition.
  • Reported results were distorted by nonrecurring items including a $480 million gain on the Norway divestiture, a $182 million LIFO credit, and other GAAP-only adjustments.
  • Operating expenses rose 14% in Q4 to $2.1 billion, raising questions about cost discipline relative to revenue growth.
Full Analysis
McKesson Corporation delivered strong fourth-quarter financial results for fiscal 2026, reporting revenue of $96.3 billion, a 6% increase compared to the prior year, and adjusted earnings per share (EPS) of $11.69, up 16%. For the full fiscal year, revenue climbed 12% to $403.0 billion, while adjusted operating profit rose 15% to $6.5 billion and total EPS increased 18% to $39.11. Management highlighted that excluding one-time gains from McKesson Ventures, core underlying EPS growth was closer to 20%, driven by broad-based expansion in oncology, biopharma services, and supply chain improvements. The company generated significant cash flow with fiscal 2026 operating cash flow at $6.2 billion and free cash flow reaching $5.4 billion. Capital return initiatives included a total of $5.1 billion returned to shareholders through dividends and buybacks, with an accelerated repurchase of $2.25 billion in the fourth quarter; board approval was granted for an additional $5.0 billion in share repurchases, bringing total capacity to approximately $7.7 billion. Growth was particularly robust in oncology and multispecialty operations, where fourth-quarter revenue jumped 35% to $12.7 billion and operating profit surged 53% to $385 million. This segment added over 570 providers in the quarter, representing its largest net increase since 2010, bolstered by acquisitions such as PRISM and Core Ventures. Biopharma services also scaled effectively, supporting a record 3.4 million patients across brand and specialty therapies, estimated to have saved customers roughly $10 billion on medication costs and prevented about 12 million prescription abandonments. The GLP-1 category remained a major growth driver with fourth-quarter distribution revenue rising 22% to $14 billion and full-year revenue increasing 27% to $53 billion, though management noted short-term volume volatility due to inventory adjustments. To maintain efficiency and resilience, McKesson continued investing in automation and artificial intelligence, including a new Montreal distribution center with advanced storage technology that helped mitigate disruptions from a major winter storm. The company also advanced its strategy to separate the Medical-Surgical business, completing financing steps like a $1 billion term loan and revolving credit facility. Apollo Global Management invested $1.25 billion for a roughly 13% stake in the new entity, valuing it at approximately $13 billion, which provides liquidity for further share repurchases. However, executives noted headwinds such as branded pharmaceutical price declines that dragged down reported revenue by about 3% in the quarter and a sequential decline in GLP-1 volumes of 4%, advising investors to look through certain GAAP-only items like a $480 million gain from Norway divestiture and an $182 million LIFO credit to gauge underlying trends.